ATE313586T1 - Mehrarmige blockcopolymere und pharmazeutische zusammensetzung - Google Patents

Mehrarmige blockcopolymere und pharmazeutische zusammensetzung

Info

Publication number
ATE313586T1
ATE313586T1 AT02761075T AT02761075T ATE313586T1 AT E313586 T1 ATE313586 T1 AT E313586T1 AT 02761075 T AT02761075 T AT 02761075T AT 02761075 T AT02761075 T AT 02761075T AT E313586 T1 ATE313586 T1 AT E313586T1
Authority
AT
Austria
Prior art keywords
block copolymers
hydrophobic
polymer segment
central core
covalently attached
Prior art date
Application number
AT02761075T
Other languages
English (en)
Inventor
Xuan Zhao
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE313586T1 publication Critical patent/ATE313586T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/22—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the initiator used in polymerisation
    • C08G2650/24—Polymeric initiators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AT02761075T 2001-01-19 2002-01-22 Mehrarmige blockcopolymere und pharmazeutische zusammensetzung ATE313586T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26275401P 2001-01-19 2001-01-19
PCT/US2002/021872 WO2003000777A2 (en) 2001-01-19 2002-01-22 Multi-arm block copolymers as drug delivery vehicles

Publications (1)

Publication Number Publication Date
ATE313586T1 true ATE313586T1 (de) 2006-01-15

Family

ID=22998880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761075T ATE313586T1 (de) 2001-01-19 2002-01-22 Mehrarmige blockcopolymere und pharmazeutische zusammensetzung

Country Status (12)

Country Link
US (6) US6730334B2 (de)
EP (1) EP1373366B1 (de)
JP (1) JP4078300B2 (de)
KR (1) KR100851270B1 (de)
AT (1) ATE313586T1 (de)
AU (1) AU2002326369B2 (de)
CA (1) CA2435301C (de)
DE (1) DE60208172T2 (de)
ES (1) ES2254717T3 (de)
MX (1) MXPA03006449A (de)
TW (1) TWI246524B (de)
WO (1) WO2003000777A2 (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
KR20040040782A (ko) * 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (de) 2003-03-05 2011-06-08 Halozyme, Inc. Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzunge, die dieses umfassen
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2005008614A (ja) * 2003-03-28 2005-01-13 Nano Career Kk 高分子ミセルを用いた眼科用ドラッグデリバリーシステム
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
TWI248947B (en) * 2003-07-21 2006-02-11 Ind Tech Res Inst Biodegradable copolymer, and polymeric micelle composition containing the copolymer
EP1525890A1 (de) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophor Komplex
CA2523987C (en) * 2003-10-10 2009-08-04 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
CN1950429B (zh) * 2004-05-05 2011-08-10 弗门尼舍有限公司 生物可降解接枝共聚物
WO2005118877A2 (en) 2004-06-02 2005-12-15 Vicus Bioscience, Llc Producing, cataloging and classifying sequence tags
EP1771205B1 (de) 2004-06-18 2016-10-26 Ambrx, Inc. Neuartige antigen-bindende polypeptide und ihre verwendungen
JP2008506703A (ja) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション ネトリン関連化合物および用途
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
EP1814924A2 (de) * 2004-10-08 2007-08-08 Firmenich Sa Amphiphile sternblockcopolymere
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7446157B2 (en) * 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
WO2006110862A2 (en) 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
KR100664558B1 (ko) 2005-05-23 2007-01-03 박기동 다관능성 양친매성 고분자 공중합체 및 이의 제조방법
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
US8728493B2 (en) * 2005-06-17 2014-05-20 Nektar Therapeutics Polymer based compositions and conjugates of non-steroidal anti-inflammatory drugs
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
KR100642220B1 (ko) * 2005-07-12 2006-11-03 광주과학기술원 사이클로덱스트린과 폴리(옥시에틸렌)의 결합체 및 그제조방법
ES2691646T3 (es) * 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP1926768B1 (de) 2005-07-18 2011-09-14 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
DE102005051342A1 (de) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Verkapselung und kontrollierte Freisetzung biologisch aktiver Wirkstoffe mit enzymatisch abbaubaren hyperverzweigten Trägerpolymeren
JP5264492B2 (ja) * 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー 超分岐ポリマーを含有する調製物
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
PT1979407E (pt) 2006-01-19 2014-10-16 Allexcel Inc Solubulização e distribuição direcionada de medicamentos com polímeros anfifilicos de automontagem
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
EP2319542B1 (de) 2006-02-21 2018-03-21 Nektar Therapeutics Segmentierte abbaubare Polymere und daraus hergestellte Konjugate
CA2996768C (en) * 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008005509A2 (en) * 2006-07-06 2008-01-10 Massachusetts Institute Of Technology Methods and compositions for altering biological surfaces
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
CN101541347B (zh) * 2006-08-02 2012-10-31 内布拉斯加大学评议会 药物载体、其合成及其使用方法
DE102006038240A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Verfahren zur Herstellung eines Komposits aus Oligo- oder Polynucleotiden und hydrophoben biodegradierbaren Polymeren sowie nach dem Verfahren erhaltenes Komposit
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
JP5336382B2 (ja) * 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US20080153982A1 (en) * 2006-12-20 2008-06-26 John Ta-Yuan Lai Vinyl-Thiocarbonate and Polyol Containing Block Copolymers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP5052919B2 (ja) * 2007-03-08 2012-10-17 成均▲館▼大學校 産學協力團 Ｐｈ及び温度敏感性のブロック共重合体ヒドロゲル
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
WO2008131131A1 (en) * 2007-04-17 2008-10-30 Micell Technologies, Inc. Stents having biodegradable layers
EP1982698A1 (de) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2431043A1 (de) 2007-05-23 2012-03-21 Amcol International Corporation Mit Cholesterin interagierende Phyllosilikate zur Unterdrückung der gastrointestinalen Cholesterinabsorption
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
CA2696996C (en) 2007-07-16 2016-03-22 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Antimicrobial constructs
US20110130822A1 (en) * 2007-07-20 2011-06-02 Orbusneich Medical, Inc. Bioabsorbable Polymeric Compositions and Medical Devices
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
EP2200613B1 (de) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazin-derivate und ihre verwendungen
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
MX2010004400A (es) * 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
AU2009268528B2 (en) * 2008-07-09 2015-11-05 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
US9991391B2 (en) * 2008-07-25 2018-06-05 The Board Of Trustees Of The Leland Stanford Junior University Pristine and functionalized graphene materials
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CN101724144A (zh) * 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (de) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents mit gesteuerter elution
CN101869712B (zh) * 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
US9572693B2 (en) 2009-05-14 2017-02-21 Orbusneich Medical, Inc. Self-expanding stent with polygon transition zone
US8013065B2 (en) * 2009-06-09 2011-09-06 International Business Machines Corporation Methods for making multi-branched polymers
EP2453834A4 (de) 2009-07-16 2014-04-16 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US20110070320A1 (en) * 2009-09-23 2011-03-24 Soonkap Hahn Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
EP2531140B1 (de) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
EP2542613A4 (de) 2010-03-01 2013-12-11 Univ British Columbia Derivatisierte hyperverzweigte polyglycerole
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8765098B2 (en) 2010-03-30 2014-07-01 International Business Machines Corporation Star polymers, methods of preparation thereof, and uses thereof
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US9109112B2 (en) 2010-06-25 2015-08-18 E I Du Pont De Nemours And Company Polyoxymethylene compositions with branched polymers
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
EP2658527B1 (de) 2010-12-30 2022-11-30 Micell Technologies, Inc. Nanopartikel und oberflächenmodifizierte partikelbeschichtungen, beschichtete ballons und verfahren dafür
EP2907504B1 (de) 2011-02-08 2017-06-28 Halozyme, Inc. Zusammensetzung und Lipidformulierung eines Hyaluronan-abbauenden Enzyms und seiner Verwendung zur Behandlung von benigner Prostatahyperplasie
US20120323311A1 (en) 2011-04-13 2012-12-20 Micell Technologies, Inc. Stents having controlled elution
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130022592A1 (en) 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US8445577B2 (en) * 2011-07-25 2013-05-21 Iowa State University Research Foundation, Inc. Amphiphilic multi-arm copolymers and nanomaterials derived therefrom
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
EP2831237B1 (de) 2012-03-30 2017-11-29 The Board of Regents of the University of Oklahoma Hochmolekulare heparosanpolymere sowie verfahren zur herstellung und verwendung davon
EP2833905B1 (de) 2012-04-04 2018-05-02 Halozyme, Inc. Kombinationbehnadlung von hyaluronidase und einem tumor-gerichteten taxane
WO2013176739A1 (en) * 2012-05-25 2013-11-28 Regents Of The University Of Minnesota Biomaterials with a sustainable surface
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
CN102861610B (zh) * 2012-09-03 2014-05-07 宁波长阳科技有限公司 一种超支化含胺基吡啶催化剂、其制备方法及其用途
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN103910874A (zh) * 2013-01-06 2014-07-09 张雅珍 一种接枝药物的聚合物的制备和用途
CN104193987A (zh) * 2013-01-21 2014-12-10 张雅珍 一种接枝药物的聚合物的制备和用途
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
US9815935B2 (en) 2013-04-15 2017-11-14 Kent State University Biodegradable side chain liquid crystal elastomers: smart responsive scaffolds (SRS) for tissue regeneration
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN104910373A (zh) * 2013-08-25 2015-09-16 张雅珍 一种新聚合物及其制备和用途
WO2015032948A1 (en) 2013-09-09 2015-03-12 Gambro Lundia Ab Separation of interference pulses from physiological pulses in a pressure signal
WO2015038966A1 (en) * 2013-09-12 2015-03-19 Regents Of The University Of Minnesota Semi-solid delivery systems
US9433638B1 (en) 2013-10-02 2016-09-06 University Of Kentucky Research Foundation Polymeric prodrug
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2016004369A1 (en) 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
CN105395483B (zh) * 2015-12-21 2018-09-28 江南大学 一种可还原降解超支化聚合物纳米胶束及其制备方法
EP3413964A4 (de) 2016-02-08 2019-12-04 Orbusneich Medical Pte. Ltd Arzneimitteleluierender ballon
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
CN105778021B (zh) 2016-04-05 2018-07-10 华南理工大学 β-环糊精基星形聚合物和制备方法及其单分子胶束诊疗一体化系统
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US20180085498A1 (en) 2016-09-23 2018-03-29 Micell Technologies, Inc. Prolonged drug-eluting products
US11027040B2 (en) * 2016-12-29 2021-06-08 Industrial Technology Research Institute Method for manufacturing a porous film, porous film and method for tissue adhesion
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
US10457759B2 (en) 2017-07-20 2019-10-29 International Business Machines Corporation Co-delivery of cholesterol lowering drugs and nutraceuticals
CN111526891B (zh) * 2017-12-27 2023-10-20 三洋化成工业株式会社 药品原料药用原料或药品用添加物和使用了它们的药品原料药或药品
CN108707212B (zh) * 2018-05-02 2020-01-07 上海交通大学 一种水溶性共轭聚合物纳米粒子的可控制备方法
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CN109608633A (zh) * 2018-11-09 2019-04-12 北京诺康达医药科技股份有限公司 一种新型的特异性多臂聚乙二醇衍生物及其制备方法
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
EP3680273B1 (de) * 2019-01-08 2022-03-09 Université de Montpellier Mit photoreaktiven gruppen funktionalisierter verzweigter blockcopolymer-photovernetzer und dessen verwendung zur formgebung von degradierbaren, für medizinische und gewebetechnische anwendungen geeigneten photovernetzten elastomeren
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN109929083B (zh) * 2019-04-10 2020-04-28 浙江大学 一种窄分子量分布的多嵌段共聚物及其制备方法
CN110078901A (zh) * 2019-05-24 2019-08-02 上海典范医疗科技有限公司 一种外消旋聚乳酸制备方法
EP3862032A1 (de) 2020-02-07 2021-08-11 Micell Technologies, Inc. Stents mit biologisch abbaubaren schichten
EP4117732A1 (de) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und verfahren zur verwendung davon
CN111759552B (zh) 2020-07-06 2025-05-13 苏州莱诺医疗器械有限公司 一种可吸收支架系统
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
KR20240004604A (ko) * 2021-04-30 2024-01-11 상하이 센후이 메디슨 컴퍼니 리미티드 중합체 및 이의 조성물
CN115475239A (zh) * 2021-05-30 2022-12-16 中国科学院上海药物研究所 一种基于tlr7激动剂偶联肽的新型冠状病毒纳米乳疫苗及其制备
CN113416302B (zh) * 2021-07-08 2022-06-17 中国科学院兰州化学物理研究所 一种硫醇-丙烯酸酯生物材料及其制备方法和应用
US20230129716A1 (en) * 2021-10-27 2023-04-27 Milliken & Company End-Modified Branched Block Copolymers As Dual-Functional Soil Surfactants and Humectants
CN114713206B (zh) * 2022-03-15 2023-11-14 沈阳工业大学 咪唑离子液体功能化星型嵌段聚合物固定相的制备及应用
KR20250160197A (ko) * 2023-03-21 2025-11-11 오큘라 테라퓨틱스, 인코포레이티드 폴리(에틸렌 글리콜) 기반 덴드리머-유사 초분지형 거대분자, 이의 제조 방법 및 용도
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US673034A (en) * 1900-08-07 1901-04-30 Russel B Sigafoos Trussed ladder.
US3101374A (en) 1958-08-19 1963-08-20 Wyandotte Chemicals Corp Polyoxyalkylene surface active agents having heteric polyoxyethylene solubilizing chains
US4278555A (en) 1978-11-15 1981-07-14 Ethyl Corporation Lubricant composition
GB2047093B (en) 1979-03-21 1983-12-07 Graham N B Controlled release compositions
JPS59155432A (ja) 1983-02-22 1984-09-04 Rikagaku Kenkyusho 易動性の大きな分子鎖を有する表面改質ポリマ−
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5135751A (en) 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5681576A (en) 1988-11-16 1997-10-28 Mdv Technologies, Inc. Method and composition for post surgical adhesion reduction
US5306501A (en) 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
DE4017688A1 (de) * 1990-06-01 1991-12-05 Bayer Ag Verbesserte funktionelle fluessigkeiten und neue polyoxyalkylenpolymere
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2087125A1 (en) * 1992-01-23 1993-07-24 Mridula Nair Chemically fixed micelles
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US5610241A (en) 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
CN1281355A (zh) 1997-12-12 2001-01-24 三阳株式会社 用于基因递送的生物可降解性混合聚合胶束
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
EP1246608A4 (de) 2000-01-05 2005-05-18 Imarx Therapeutics Inc PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
FI109162B (fi) * 2000-06-30 2002-05-31 Nokia Corp Menetelmä ja järjestely konvoluutiokoodatun koodisanan dekoodaamiseksi
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles

Also Published As

Publication number Publication date
US8338545B2 (en) 2012-12-25
US20120046422A1 (en) 2012-02-23
US8586681B2 (en) 2013-11-19
DE60208172D1 (de) 2006-01-26
ES2254717T3 (es) 2006-06-16
US7589157B2 (en) 2009-09-15
WO2003000777A2 (en) 2003-01-03
KR20040032092A (ko) 2004-04-14
JP2004531627A (ja) 2004-10-14
US20080234430A1 (en) 2008-09-25
WO2003000777A3 (en) 2003-05-01
KR100851270B1 (ko) 2008-08-08
US6730334B2 (en) 2004-05-04
US20040170595A1 (en) 2004-09-02
CA2435301A1 (en) 2003-01-03
US6838528B2 (en) 2005-01-04
CA2435301C (en) 2010-04-13
MXPA03006449A (es) 2004-10-15
US20020156047A1 (en) 2002-10-24
TWI246524B (en) 2006-01-01
US20090299050A1 (en) 2009-12-03
EP1373366B1 (de) 2005-12-21
JP4078300B2 (ja) 2008-04-23
US20130144014A1 (en) 2013-06-06
AU2002326369B2 (en) 2007-03-15
DE60208172T2 (de) 2006-07-13
US8071692B2 (en) 2011-12-06
EP1373366A2 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
DE60208172D1 (de) Mehrarmige blockcopolymere und pharmazeutische zusammensetzung
WO2003044076A8 (en) Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
ATE461961T1 (de) Mehrarmige polypeptid-poly(ethylenglykol)- blockcopolymere als arzneistoffzufuhrvehikel
CA2430481A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
CY1110264T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
WO2001049258A3 (en) Methods and compositions for improved delivery devices
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
UY25896A1 (es) Composición farmacéutica bajo la forma de una dispersión sólida incluyendo una rapamicina y un vehículo
AU2001295017A1 (en) Solid dose nanoparticulate compositions
TW200610540A (en) Pharmaceutical compositions
BR0212475A (pt) Composições farmacêuticas
EP1292709A4 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
EP1196149A4 (de) IN ORGANISCHEN LÖSEMITTELN LÖSLICHE BIOLOGISCH ABBAUBARE POLY (ALKYLENOXID)- POLY (p-DIOXANON) BLOCKCOPOLYMERE SOWIE DIESE ENTHALTENDE ZUSAMMENSETZUNG ZUR ARZNEISTOFFVERABREICHUNG
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
IL157531A0 (en) Erodible polymers for injection
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
WO2004112713A3 (en) Drug polymer complexes
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
ATE385801T1 (de) Biologisch abbaubare poly(ortho-ester) von di(ketenacetalen) auf dioxangrundlage, sowie sie enthaltende blockcopolymere
KR101066763B1 (ko) 온도 반응성 전달계
Tarawneh et al. Characterization of Chlorhexidine‐Impregnated Cellulose‐Based Hydrogel Films Intended for the Treatment of Periodontitis
ATE386725T1 (de) Heterocyclylverbindungen
CA2523987A1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2017151664A1 (en) Pharmaceutical compositions for fluoroquinolone drug delivery

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties